Cost-effectiveness of dengue vaccination in Puerto Rico.

An effective and widely used vaccine could reduce the burden of dengue virus (DENV) around the world. DENV is endemic in Puerto Rico, where the dengue vaccine CYD-TDV is currently under consideration as a control measure. CYD-TDV has demonstrated efficacy in clinical trials in vaccinees who had prio...

Full description

Bibliographic Details
Published in:PLOS Neglected Tropical Diseases
Main Authors: Guido España, Andrew J Leidner, Stephen H Waterman, T Alex Perkins
Format: Article in Journal/Newspaper
Language:English
Published: Public Library of Science (PLoS) 2021
Subjects:
Online Access:https://doi.org/10.1371/journal.pntd.0009606
https://doaj.org/article/2e34002b38d04636b6e0121621a58d7c
id ftdoajarticles:oai:doaj.org/article:2e34002b38d04636b6e0121621a58d7c
record_format openpolar
spelling ftdoajarticles:oai:doaj.org/article:2e34002b38d04636b6e0121621a58d7c 2023-05-15T15:10:13+02:00 Cost-effectiveness of dengue vaccination in Puerto Rico. Guido España Andrew J Leidner Stephen H Waterman T Alex Perkins 2021-07-01T00:00:00Z https://doi.org/10.1371/journal.pntd.0009606 https://doaj.org/article/2e34002b38d04636b6e0121621a58d7c EN eng Public Library of Science (PLoS) https://doi.org/10.1371/journal.pntd.0009606 https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0009606 https://doaj.org/article/2e34002b38d04636b6e0121621a58d7c PLoS Neglected Tropical Diseases, Vol 15, Iss 7, p e0009606 (2021) Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 article 2021 ftdoajarticles https://doi.org/10.1371/journal.pntd.0009606 2022-12-31T16:22:38Z An effective and widely used vaccine could reduce the burden of dengue virus (DENV) around the world. DENV is endemic in Puerto Rico, where the dengue vaccine CYD-TDV is currently under consideration as a control measure. CYD-TDV has demonstrated efficacy in clinical trials in vaccinees who had prior dengue virus infection. However, in vaccinees who had no prior dengue virus infection, the vaccine had a modestly elevated risk of hospitalization and severe disease. The WHO therefore recommended a strategy of pre-vaccination screening and vaccination of seropositive persons. To estimate the cost-effectiveness and benefits of this intervention (i.e., screening and vaccination of seropositive persons) in Puerto Rico, we simulated 10 years of the intervention in 9-year-olds using an agent-based model. Across the entire population, we found that 5.5% (4.6%-6.3%) of dengue hospitalizations could be averted. However, we also found that 0.057 (0.045-0.073) additional hospitalizations could occur for every 1,000 people in Puerto Rico due to DENV-naïve children who were vaccinated following a false-positive test results for prior exposure. The ratio of the averted hospitalizations among all vaccinees to additional hospitalizations among DENV-naïve vaccinees was estimated to be 19 (13-24). At a base case cost of vaccination of 382 USD, we found an incremental cost-effectiveness ratio of 122,000 USD per QALY gained. Our estimates can provide information for considerations to introduce the CYD-TDV vaccine in Puerto Rico. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic PLOS Neglected Tropical Diseases 15 7 e0009606
institution Open Polar
collection Directory of Open Access Journals: DOAJ Articles
op_collection_id ftdoajarticles
language English
topic Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
spellingShingle Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
Guido España
Andrew J Leidner
Stephen H Waterman
T Alex Perkins
Cost-effectiveness of dengue vaccination in Puerto Rico.
topic_facet Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
description An effective and widely used vaccine could reduce the burden of dengue virus (DENV) around the world. DENV is endemic in Puerto Rico, where the dengue vaccine CYD-TDV is currently under consideration as a control measure. CYD-TDV has demonstrated efficacy in clinical trials in vaccinees who had prior dengue virus infection. However, in vaccinees who had no prior dengue virus infection, the vaccine had a modestly elevated risk of hospitalization and severe disease. The WHO therefore recommended a strategy of pre-vaccination screening and vaccination of seropositive persons. To estimate the cost-effectiveness and benefits of this intervention (i.e., screening and vaccination of seropositive persons) in Puerto Rico, we simulated 10 years of the intervention in 9-year-olds using an agent-based model. Across the entire population, we found that 5.5% (4.6%-6.3%) of dengue hospitalizations could be averted. However, we also found that 0.057 (0.045-0.073) additional hospitalizations could occur for every 1,000 people in Puerto Rico due to DENV-naïve children who were vaccinated following a false-positive test results for prior exposure. The ratio of the averted hospitalizations among all vaccinees to additional hospitalizations among DENV-naïve vaccinees was estimated to be 19 (13-24). At a base case cost of vaccination of 382 USD, we found an incremental cost-effectiveness ratio of 122,000 USD per QALY gained. Our estimates can provide information for considerations to introduce the CYD-TDV vaccine in Puerto Rico.
format Article in Journal/Newspaper
author Guido España
Andrew J Leidner
Stephen H Waterman
T Alex Perkins
author_facet Guido España
Andrew J Leidner
Stephen H Waterman
T Alex Perkins
author_sort Guido España
title Cost-effectiveness of dengue vaccination in Puerto Rico.
title_short Cost-effectiveness of dengue vaccination in Puerto Rico.
title_full Cost-effectiveness of dengue vaccination in Puerto Rico.
title_fullStr Cost-effectiveness of dengue vaccination in Puerto Rico.
title_full_unstemmed Cost-effectiveness of dengue vaccination in Puerto Rico.
title_sort cost-effectiveness of dengue vaccination in puerto rico.
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doi.org/10.1371/journal.pntd.0009606
https://doaj.org/article/2e34002b38d04636b6e0121621a58d7c
geographic Arctic
geographic_facet Arctic
genre Arctic
genre_facet Arctic
op_source PLoS Neglected Tropical Diseases, Vol 15, Iss 7, p e0009606 (2021)
op_relation https://doi.org/10.1371/journal.pntd.0009606
https://doaj.org/toc/1935-2727
https://doaj.org/toc/1935-2735
1935-2727
1935-2735
doi:10.1371/journal.pntd.0009606
https://doaj.org/article/2e34002b38d04636b6e0121621a58d7c
op_doi https://doi.org/10.1371/journal.pntd.0009606
container_title PLOS Neglected Tropical Diseases
container_volume 15
container_issue 7
container_start_page e0009606
_version_ 1766341252304863232